Articles By Rob Wright, Chief Editor 2011-2021

-
The Drug Pricing Dilemma, Pfizer, And President Trump7/13/2018
An op-ed regarding Pfizer’s drug-pricing actions, President Trump, and the potential impact on the biopharmaceutical industry’s image.
-
At The End Of The Day — And Other Phrases That Could Be Used Less7/9/2018
A review of buzzwords and phrases that should be used less in the world of business.
-
Sage Therapeutics — Sitting On The Brink Of CNS Breakthroughs7/5/2018
Jeff Jonas, M.D., CEO of Sage Therapeutics, discusses how the company is preparing to launch a new CNS product likely to change the paradigm for how postpartum depression is treated.
-
Dermatology — A Growth Opportunity For Those Willing To Risk Colossal Failure7/5/2018
Tom Wiggans, founder, chairman, and CEO of Dermira, provides an overview of the dermatology market, the impetus for founding Dermira, and transparently shares his experience regarding his company’s Phase 3 clinical trial failures.
-
What Will The Next 10 Years Bring For Biopharma?7/5/2018
The biopharma industry has changed significantly during the past 10 years, and so has Life Science Leader. What will the next decade have in store for issues such as drug pricing and new therapeutic advances?
-
Did BIO 2018 Do More Than Make History In Boston?6/14/2018
BIO 2018 does more than make business meeting history, but facilitates personal connections that can lead toward doing better business.
-
BIO 2018 — A View Through The Eyes Of An Aspiring Biomedical Engineer6/12/2018
Miriam Massaad, a biomedical engineering student at Boston University, shares her experiences as a first-time attendee at the 2018 BIO International Convention and Conference in Boston.
-
What Is MassBio Doing To Promote Greater Diversity And Inclusion?6/12/2018
Robert Coughlin, president and CEO of MassBio, discusses his organization’s approach to diversity and inclusion.
-
Research Into The State Of Innovation In Highly Prevalent Chronic Diseases6/11/2018
Dave Thomas, managing director for industry research and analysis at the Biotechnology Innovation Organization (BIO), discusses chronic disease research and other industry trends.